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Summary Estimates were made of the rates at which cancer cells were released directly into the renal vein in
patients undergoing radical nephrectomy for primary renal cancer. Cancer cells were counted in blood
samples taken from the renal vein using a density gradient centrifugation procedure, and identified using
immunocytochemical techniques, on the basis of their cytoskeletal intermediate filament proteins. Cancer cells
were released as single cells and multicell emboli in 8/10 patients, in numbers varying widely between 14-7509
emboli ml - of blood. Despite a calculated median input into the metastatic process of 3.7 x I07 cancer cells
per day for at least 180 days, only 3/10 patients had extraperitoneal metastases prior to surgery and only of
the remaining disease-free patients subsequently developed distant metastases over a maximum 35 month
period. These results are discussed in terms of primary tumour kinetics and metastatic inefficiency.
Animal studies in which cancer cells are introduced into the
circulation via i.v. injections have shown that many
malignant cells are required to produce relatively few tumour
nodules in the lungs (Warren & Gates, 1936; Zeidman et al.,
1950). Other studies, in which the numbers of cancer cells
shed spontaneously into the bloodstream from solid tumours
were monitored by means of bioassay (Mayhew & Glaves,
1984; Glaves & Mayhew, 1984) or direct counting
procedures (Liotta et al., 1974; Butler & Gullino, 1975;
Glaves, 1983a), also indicate that the numbers of malignant
cells potentially seeded into an organ may be orders of
magnitude more than the numbers of spontaneous
metastases which subsequently develop. These findings and
others have given rise to the concept of 'metastatic
inefficiency' (Weiss, 1980; 1986).
In contrast to the animal studies, there are very few
reliable estimates of cancer cell input into the metastatic
cascade in humans. Although many attempts were made to
estimate the release of cancer cells into the bloodstream in
the decade following Engell's pioneering studies (Engell,
1955), many of these estimates were unreliable because of
various methodologic problems associated with cancer cell
isolation, deterioration, identification and enumeration, as
discussed elsewhere (Nadel, 1965; Salsbury, 1975). In
addition, in many of these earlier studies, samples of
peripheral blood were taken from antecubital veins, resulting
in underestimates of the total numbers of circulating cancer
cells since the vast majority of them would have been
trapped in pulmonary capillaries before reaching this
segment of the circulation.
As reliable estimates of circulating cells are required to
gauge the overall efficiency of the metastatic process in
humans, we have attempted to avoid the difficulties
encountered in earlier investigations. Thus, cancer cells were
isolated using a previously developed, efficient density
gradient separation procedure (Glaves, 1983a), and we have
avoided organ-trapping artifacts, by direct blood-sampling
from the renal vein, in patients undergoing radical
nephrectomy for primary renal cancer.
Materials and methods
Blood samples
Blood samples of 3- 0ml from 10 patients were collected
into 10ml syringes containing 1000 units of heparin directly
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from a renal vein during surgery, just prior to nephrectomy
for renal carcinoma.
Separation ofcarcinoma cellsfrom blood
The techniques for collection and enumeration of malignant
cells from blood have previously been described in detail
(Glaves, 1983a). Briefly, anticoagulated blood was diluted
1:1 with RPMI 1640 medium and 5 ml aliquots were layered
onto a discontinuous gradient of Percoll (Pharmacia, NJ).
After centrifugation for 30min at 800g the fraction
containing cancer cells was aspirated, washed, resuspended
in foetal calf serum and 0.05ml aliquots collected by gravity
onto polycarbonate filters (Nuclepore, CA). Filters were
fixed in methanol and stained by indirect immuno-
fluorescence to identify carcinoma cells on the basis of their
cytoskeletal intermediate filament proteins. Controls included
normal human blood subjected to the same procedures. The
numbers of cancer cells per ml original blood were calculated
on the basis of dilution and cell counts per filter, allowing
for the efficiency of recovery. The efficiency of collection was
determined by subjecting mixtures of known numbers of
freshly isolated human renal carcinoma cells with normal
human blood, to the complete separation and filter
enumeration procedure. These experiments were made with
cell suspensions containing 90% cancer cells obtained from
enzymatically dissociated tumour tissue after exposure to
0.25% neutral protease for 20min at 37°C. For each
experiment 102, 103 or 104 tumour cells were seeded
appropriately into aliquots of normal human blood prior to
separation and enumeration. Recoveries from duplicate
samples at each cell dose were within similar ranges and the
mean efficiency of combined recoveries was 28.0 +2.2%.
Allowances could therefore be made for recovery loss in
calculating the numbers of cancer cells released into renal
veins (Glaves, 1983a).
Indirect immunofluorescence assays ofrecovered cancer cells
As previously described, a mouse monoclonal antibody
(AE3) against keratins (Cooper et al., 1985) was used in
indirect immunofluorescence assays performed for detection
of circulating mouse carcinoma cells (Glaves et al., 1986).
Fluorescein isothiocyanate-conjugated goat anti-mouse
immunoglobulin antiserum (Cappel Laboratories, PA) was
used as the secondary antibody. AE3 detects all basic human
keratins and cells of epithelial origin, including carcinoma
cells, have cytoskeletal intermediate filaments which contain
at least one basic keratin. The reactivity of AE3 with renal
carcinoma cells was tested in indirect immunofluorescence
assays with tumour tissues collected at the time of
Br. J. Cancer (1988), 57, 32-35 (D The Macmillan Press Ltd., 1988HAEMATOGENOUS SPREAD OF RENAL CANCER 33
nephrectomy, fixed in 95% ethanol and embedded in
paraffin at low (56°C) temperature.
Results
Confirmation of the reactivity of AE3 antibody with renal
carcinoma cells is illustrated in Figure 1 which shows the
results of indirect immunofluorescence assays with carcinoma
tissue from patient KT-1. Stromal cells are not stained since
they are of mesenchymal origin and express vimentin as their
major intermediate filament protein (Lazarides, 1980).
Both single cancer cell emboli and multicell emboli were
detected in blood samples taken from renal veins, as
illustrated in Figure 1, and a summary of the numbers of
cancer cell emboli recovered is given in Table I.
Disseminating cancer cells were present in 8/10 patients and
as few as 14 emboli per ml blood were detected, although
there were wide variations in the numbers of circulating
emboli between individual patients. Multicell emboli
comprised of 2 to over 15 cells were present in 5 of the 8
patients with detectable cells in their renal venous effluent;
independent studies have shown that the cancer cell
separation procedures used here does not result in the
disproportionate loss or gain of cell clumps (Glaves, 1983a).
The extent of metastasis in each patient was clinically
assessed before and during the operation, at which time the
assay for circulating cancer cells was made. Subsequent
metastatic status was assessed during patient follow-up visits
or at autopsy. Only 3 patients had clinically detectable
extraperitoneal metastases prior to assay and 5 patients
remained overtly disease-free for up to 35 months (Table I).
Discussion
Patients with renal adenocarcinomas were selected since,
unlike tumours at many other sites, the venous effluent is
usually restricted to a single renal vein, and since average
renal blood flow rates of 500mlmin- through each kidney
have been documented (Altman & Dittmer, 1971); estimates
of the total output of released cancer cells can be made.
Also, haematogenous dissemination of cancer cells is
probably the major pathway in the development of renal
carcinoma metastases.
The unequivocal identification of circulating cancer cells
by standard cytological techniques may be ambiguous.
Therefore, we have used immunologic probes to identify
Figure 1 Indirect immunofluorescence staining with antiserum to keratins. (a) Primary renal adenocarcinoma tissue, x 100; (b-d)
single adenocarcinoma cells recovered from renal venous effluent, x 320; (e-h) Multicell emboli recovered from renal venous
effluent, x 320.34 D. GLAVES et al.
Table I Disseminating renal carcinoma emboli
Emboliml
Tumour diam. Histologic Spreadprior renal effluent Post-surgical
Patient (cm) diagnosis to surgery (% multicellular) metastases
KT-l 5 clear cell lung; 341 (0) expired 2.5mo.
adenocarcinoma thoracic spine
stage IV
KT-2 10 clear cell extension to 7309 (20) none detected a) 28mo.
adenocarcinoma hilar vein
stage III
KT-3 8 clear cell perinephric fat none detected none detected a,) 35mo.
adenocarcinoma
stage III
KT-4 9 clear cell none evident 553 (5) multiple
adenocarcinoma lung @ 14mo.
stage II
KT-5 6.8 transitional cell lung, 270 (11) multiple lung, pancreas,
carcinoma regional lymph lymph nodes, right
stage IV nodes, ureter ventricle, adrenal @
4mo. (expired)
KT-6 10 clear cell perinephric fat, 51 (0) multiple brain @ 7mo.
adenocarcinoma bilateral adrenals (18mo. expired)
stage III (no autopsy data)
KT-7 5.8 clear cell lung, 25 (12) multiple lung, femur,
adenocarcinoma extension renal capsule fibula @ 12mo. (13 mo.
stage IV expired)
KT-8 7.3 clear cell extension renal vein, 14 (0) none detected ® 18 mo.
adenocarcinoma perinephric fat
stage III
KT-9 6 clear cell none evident none detected none detected @ 19mo.
adenocarcinoma
stage I
KT-10 6 clear cell extension renal vein 315 (3) none detected (a, 7mo.
adenocarcinoma
stage III
carcinoma cells on the basis of their intermediate filament
keratins; these proteins are not expressed by cells of bone
marrow origin or by endothelial cells (Lazarides, 1980)
which could conceivably be mistaken for cancer cells.
Although examination of fixed material does not permit
evaluation of cancer cell viability, animal studies involving
both direct counts of cancer cells and their bioassay (Glaves,
1983a; Glaves & Mayhew, 1984), indicate that the majority
of cells freshly released into major blood vessels may well be
viable and potentially tumorigenic. In connection with
tumorigenicity, it is important to note that in those patients
with disseminating cancer emboli, as many as 20% were
multicellular and experimental animal studies indicate that
clumps of cancer cells are more efficient in generating
metastases than equivalent numbers of single cancer cells
(Fidler, 1973; Liotta et al., 1976).
Studies with experimental animal tumours indicate that
70-95% of cancer cells given by tail vein injection are
arrested in the first downstream capillary bed, the
pulmonary microvasculature (Fidler, 1970; Glaves, 1980).
The vast majority of those cancer cells arrested in the lungs
are rapidly killed due to a variety of mechanical (Sato et al.,
1976; Weiss, 1987) and host mediated (Riccardi et al., 1979;
Glaves, 1983b) factors, with the net result that sub-
tumorigenic doses of cancer cells are delivered to other
organs (Weiss, 1980). Such aspects of cancer cell delivery
have been held to account for the metastatic patterns of
several cancers, including kidney carcinomas (Weiss, 1985),
in which arterial metastases in other organs are more likely
to occur in the presence of lung metastases which constitute
generalizing sites and act as a source of disseminating cancer
cells.
In order to determine the efficiency of that part of the
process whereby (pulmonary) metastases are generated by
circulating cancer cells, numerical estimates are required of
both cancer cell input and metastasis formation. Our
approach has been to calculate the tumour load in the lungs
under conditions of 100% efficiency, when every cancer cell
delivered was tumorigenic, and to compare this estimate with
clinical observations. We have taken an admittedly simplistic
view of tumour kinetics, in which in the absence of more
detailed data it is assumed that cancer cells proliferate in an
exponential manner without loss. The degree of inaccuracy
of these assumptions is fully discussed by Steel (1977a) and
others. On the basis of a 60-day doubling time (Steel, 1977b)
and our stated assumptions, it would take 180 days for a
5cm diameter carcinoma which is the smallest in our series,
to grow into a 10cm lesion which is the largest. The present
studies indicate that lesions in this size range release
3.7 x 107 cancer cells per 24h into the renal vein, according
to pro-rated cancer cell counts from Table I. Therefore, a
total of -7 x 109 cells would have been released during the
180 day doubling period (i.e., 180 x 3.7 x 107). However, this
may well be an underestimate because cancer cells may be
released into the venous system by tumours considerably less
than 5cm diameter including occult primary lesions (Glaves,
1983a). Median cell counts are used, since analogous
experiments with mice (Glaves, 1983; Mayhew & Glaves,
1984; Glaves & Mayhew, 1984) indicate that cancer cell
release is a fluctuating process which is reflected by wide
variations in the numbers of circulating cancer cells in single-
point samples, as was observed in the present study. On this
basis, using patient KT-3 as an example, if all the cancer
cells delivered to the lungs prior to nephrectomy had
undergone a further 18 doublings, a total of _1015 cancer
cells would be present. This corresponds to 1000 times the
weight of the lungs. In fact, no new lung lesions were
detected 35 months after operation, in radiographs capable
of detecting 1 cm diameter lesions containing 109 cells.
Thus, in spite of the recognized inaccuracies of theHAEMATOGENOUS SPREAD OF RENAL CANCER 35
calculations, the overall impression is that of the millions of
cancer cells arriving in the lungs, few form overt metastases.
Comparisons may be made between these estimates of the
efficiency of metastasis from human renal carcinomas and
results obtained from analogous experiments with B16
melanomas and Lewis lung carcinomas in mice (Glaves,
1983). These latter results were based on direct observations,
and did not involve use of calculations of tumour kinetics.
Accordingly, following i.m. injection of 105 melanoma cells
into groups of mice, counts of circulating cancer cells,
recovered from blood samples taken from the right ventricle,
were obtained from the time of injection to the maximum
survival time of 35 days. Circulating cancer cells were
detected from day 3 through day 35, and over this period a
median of 2.4 x107 melanoma cells was released into the
blood. On examination of lungs under a dissection
microscope, where lesions of 0.1 mm diameter can be
detected, only between 0 to 1 lesion per mouse was detected.
Thus, the efficiency of this, observed, part of the metastatic
process was less than 10-7. A corresponding value of 10-6
was obtained for Lewis lung carcinomas in mice. Metastatic
inefficiency of human cancer also was observed in other
studies (Tarin et al., 1984) on patients with malignant
ascites, in whom peritoneovenous shunts were used to
alleviate abdominal distension so that patients effectively
received autotransfusions of cancer cells over periods of
weeks. Distant metastases were not detected in 8/15 of these
patients although only one patient survived longer than 9
months.
Studies on the kinetics of solid tumour indicate that cell
loss is a common feature of growing cell populations (Steel,
1977c). Cell loss is partly due to cell death and partly to
release of cancer cells from the primary lesions. Cell loss is
usually measured indirectly by morphologic examination or
inferred from discrepancies between rates of cell division and
the size of the total population. However, the present studies
provide a quantitative estimate of oine specific component of
cell loss, that due to release by intravasation; in the case of a
10cm diameter spheroidal tumour (KT-6, Table I) with an
approximate volume of 150ml, only 0.04ml (=3.7 x 107) of
cancer cells are released per day, corresponding to a daily
loss by intravasation of -0.03%.
Although measurements of cancer cell intravasation are
conceptually simple, reliable quantitative data of this type
upon which kinetics of metastasis in human cancers can be
based, have previously not been available.
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